INOVIQ Ltd (FRA:EGQ0)

Market Cap	32.73M
Revenue (ttm)	1.01M
Net Income (ttm)	-3.87M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Average Volume	n/a
Open	0.2140
Previous Close	0.1950
Day's Range	0.2140 - 0.2140
52-Week Range	0.1610 - 0.3140
Beta	n/a
RSI	66.58
Earnings Date	Feb 18, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can...

• Industry: Gold And Silver Ores
• Founded: 2016
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EGQ0

Financial Performance

In 2025, INOVIQ's revenue was 1.82 million, an increase of 16.25% compared to the previous year's 1.56 million. Losses were -6.93 million, 5.77% more than in 2024.

Financial numbers in AUD